Close Menu

NEW YORK (GenomeWeb) – Precision oncology diagnostic firm MolecularMD has received authorization from the US Food and Drug Administration for a test to help physicians determine whether a patient with chronic myeloid leukemia (CML) can stop treatment with Novartis' drug Tasigna (nilotinib). 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.